
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC is poised for continued revenue growth through 2030, primarily driven by lower royalties from Invega and the acquisition of Lumryz, which is expected to generate significant annualized sales of approximately $265-$275 million by 2025. Furthermore, the company's pipeline includes promising products such as alixorexton, which has demonstrated encouraging efficacy data, enhancing the potential for long-term growth beyond 2025. The acquisition of Lumryz not only offers immediate profitability but also strengthens Alkermes’ commercial opportunities without adversely impacting its balance sheet, contributing to an overall positive outlook for the company.
Bears say
Alkermes PLC faces a negative outlook primarily due to anticipated sales stagnation of its lead product, Lumryz, which is expected to peak at approximately $600 million in 2030 before experiencing annual declines associated with the loss of exclusivity in 2037. Risks such as the potential failure of the orexin program, erosion of its royalty business, and the effectiveness of its proprietary products add further pressure on future earnings, compounded by a significant reliance on Medicaid revenue amid regulatory uncertainties. Additionally, increasing competition from other orexin 2 receptor agonists and shifts in patient preferences may hinder Lumryz's market growth, suggesting a potential mismatch between current share pricing and the company’s long-term cash flow outlook.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares